Does yohimbine hydrochloride facilitate fear extinction in virtual reality treatment of fear of flying? a randomized placebo-controlled trial

Psychotherapy and Psychosomatics

Volumn 81, Issue 1, 2011, Pages 29-37

  Meyerbroeker, Katharina ^a   Powers, Mark B ^a   Van Stegeren, Anda ^a   Emmelkamp, Paul M G ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Cognitive behavioral therapy; Exposure; Fear extinction; Norepinephrine; Placebo; Randomized clinical trial; Virtual reality; Yohimbine hydrochloride

Indexed keywords

AMYLASE; NORADRENALIN; YOHIMBINE;

ADULT; ANXIETY; ARTICLE; CONTROLLED STUDY; FEAR OF FLYING; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PHOBIA; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRTUAL REALITY;

ADOLESCENT; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ADULT; AEROSPACE MEDICINE; AGED; ANALYSIS OF VARIANCE; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXTINCTION, PSYCHOLOGICAL; FEAR; HUMANS; IMPLOSIVE THERAPY; MIDDLE AGED; NOREPINEPHRINE; PHOBIC DISORDERS; PLACEBOS; QUESTIONNAIRES; SALIVARY ALPHA-AMYLASES; TREATMENT OUTCOME; USER-COMPUTER INTERFACE; YOHIMBINE; YOUNG ADULT;

EID: 81555232796     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000329454     Document Type: Article

References (50)

1. Rescorla RA: Experimental extinction; in Mowrer RR, Klein SB (ed): Handbook of Contemporary Learning Theories. Mahwah, Erlbaum, 2001, pp 119-154.
2. Bouton ME: Context, ambiguity, and unlearning: sources of relapse after behavioral extinction. Biol Psychiatry 2002; 52: 976-986. (Pubitemid 35356355)
3. Emmelkamp PMG, Bouman TK, Scholing A: Anxiety Disorders: A Practioner's Guide. Chichester, John Wiley & Sons, 1992.
4. Norton PJ, Price EC: A meta-analytic review of adult cognitive behavioral treatment outcome across anxiety disorders. J Nerv Ment Dis 2007; 195: 521-531. (Pubitemid 46945492)
5. Powers MB, Sigmarsson SR, Emmelkamp PMG: A meta-analytic review of psychological treatments for social anxiety disorder. Int J Cogn Ther 2008; 12: 94-113.
6. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, et al: Cognitive enhancers as aduncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 2004; 61: 1136-1144. (Pubitemid 39463415)
7. Hofmann SG, Meuret AE, Smits JA, Simon NM, Pollack MH, Eisenmenger K, et al: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 2006; 63: 298-304. (Pubitemid 43345354)
8. Guastella AJ, Richardson R, Lovibond PF, Rapee RM, Gaston JE, Mitchell P, et al: A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol Psychiatry 2008; 63: 544-549.
9. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, et al: D-Cycloserine augmented exposure therapy for obsessivecompulsive disorder. Biol Psychiatry 2007; 62: 835-838. (Pubitemid 47488217)
10. Storch EA, Merlo LJ, Bengtson M, Murphy TK, Lewis MH, Yang MC, et al: D-Cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2007; 22: 230-237. (Pubitemid 46801947)
11. Wilhelm S, Buhlmann U, Tolin DF, Meunier SA, Pearlson GD, Reese HE, et al: Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am J Psychiatry 2008; 165: 335-341. (Pubitemid 351704489)
12. Otto MW, Tolin DF, Simon NM, Pearlson GD, Basden S, Meunier SA, et al: Efficacy of D-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry 2010; 67: 365-370.
13. Siegmund A, Golfels F, Finck C, Halisch A, Räth D, Plag J, Ströhle A: D-Cycloserine does not improve but might slightly speed up the outcome of in-vivo exposure therapy in patients with severe agoraphobia and panic disorder in a randomized double blind clinical trial. J Psychiatr Res DOI: 10.1016/j.jpsychires. 2011.01.020.
14. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, et al: Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 2002; 5: 301-307. (Pubitemid 35470350)
15. Cain CK, Blouin AM, Barad M: Adrenergic transmission facilitates extinction of conditional fear in mice. Learn Mem 2004; 11: 179-187. (Pubitemid 38456600)
16. Morris RW, Bouton ME: The effect of yohimbine on the extinction of conditioned fear: a role for context. Behav Neurosci 2007; 121: 501-514. (Pubitemid 47445103)
17. O'Carroll RE, Drysdale E, Cahill L, Shajahan P, Ebmeier KP: Stimulation of the noradrenergic system enhances and blockade reduces memory for emotional material in man. Psychol Med 1999; 29: 1083-1088. (Pubitemid 29469298)
18. Southwick SM, Davis M, Horner B, Cahill L, Morgan CA, Gold PE, Bremner JD, Charney DC: Relationship of enhanced norepinephrine activity during memory consolidation to enhanced long-term memory in humans. Am J Psychiatry 2002; 159: 1420-1422. (Pubitemid 34832726)
19. Powers MB, Smits JAJ, Otto MW, Sanders C, Emmelkamp PMG: Facilitation of fear extinction in phobic participants with a novel cognitive enhancer: a randomized placebo controlled trial of yohimbine augmentation. J Anxiety Disord 2009; 23: 350-356.
20. Holmes A, Quirk GJ: Pharmacological facilitation of fear extinction and the search for adjunct treatments for anxiety disorders-the case of yohimbine. Trends Pharmacol Sci 2009; 31: 2-7.
21. Charney DS, Woods SW, Goodman WK, Henninger GR: Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 1987; 144: 1030-1036. (Pubitemid 17143562)
22. Peskind ER, Wingersson D, Murray S, Pascually M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA: Effects of Alzheimer's disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 1995; 52: 774-782.
23. Van Stegeren AH, Rohleder N, Everaerd W, Wolf OT: Salivary alpha amylase as marker for adrenergic activity during stress: effect of betablockade. Psychoneuroendocrinology 2006; 31: 137-141. (Pubitemid 41668902)
24. Mueller D, Olivera-Figueroa LA, Pine DS, Quirk GJ: The effects of yohimbine and amphetamine on fear expression and extinction in rats. Psychopharmacology 2009; 204: 599-606.
25. Otto MW, Basden SL, McHugh K, Kantak KM, Deckersbach T, Cather C, Goff DC, Hofmann SG, Berry AC, Smits JAJ: Effects of D-cycloserine administration on weekly nonemotional memory tasks in healthy participants. Psychother Psychosom 2009; 78: 49-54.
26. Meyerbröker K, Emmelkamp PMG: Virtual reality exposure therapy in anxiety disorders: a systematic review of process-and-outcome studies. Depress Anxiety 2010; 27: 933-944.
27. Rothbaum BO, Hodges L, Anderson P, Price L, Smith S: Twelve-months follow-up of virtual reality and standard exposure therapies for fear of flying. J Consult Clin Psychol 2002; 70: 428-432. (Pubitemid 34274887)
28. Mühlberger A, Wiedemann G, Pauli P: Efficacy of a one-session virtual reality exposure treatment for fear of flying. Psychother Res 2003; 13: 323-336. (Pubitemid 40990844)
29. Rothbaum BO, Zimand E, Hodges L, Lang D, Wilson J: Virtual reality exposure therapy and standard (in vivo) exposure therapy in the treatment of fear of flying. Behav Ther 2006; 37: 80-90. (Pubitemid 44141947)
30. Mühlberger A, Weik A, Pauli P, Wiedemann G: One-session virtual reality exposure treatment for fear of flying: 1-year follow-up and graduation flight accompaniment effects. Psychother Res 2006; 16: 26-40. (Pubitemid 43135566)
31. Krijn M, Emmelkamp PMG, Olafsson RP, Bouwman M, van Gerwen LJ, Spinhoven P, Schuemie MJ, van der Mast CAPG: Fear of flying treatment methods: virtual reality exposure vs. cognitive behavioral therapy. Aviat Space Environ Med 2007; 78: 121-128. (Pubitemid 46213109)
32. Parsons TD, Rizzo AA: Affective outcomes of virtual reality exposure therapy for anxiety and specific phobias: a meta-analysis. J Behav Ther Exp Psychiatry 2008; 39: 250-261. (Pubitemid 351766757)
33. Powers MB, Emmelkamp PMG: Virtual reality exposure therapy for anxiety disorders: a meta-analysis. J Anxiety Disord 2008; 22: 561-569. (Pubitemid 351375357)
34. Nater UM, Rohleder N: Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology 2009; 34: 486-496.
35. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Text Revision, ed 4. Washington, APA, 2000.
36. Wolpe J: The Practice of Behavior Therapy, ed 4. New York, Pergamon Press, 1990.
37. Venhuis BJ, Barends DM, Zwaagstra ME, de Kaste D: Recent developments in counterfeits and imitations of Viagra, Cialis and Levitra (RIVM report 370030001/2007). Amsterdam, Dutch Health Care Inspectorate (IGZ), 2007.
38. Vasa RA, Pine DS, Masten CL, Vythilingam M, Collin C, Charney DS, Neumeister A, Mogg K, Bradley BP, Bruck M, Monk CS: Effects of yohimbine and hydrocortisone on panic symptoms, autonomic responses, and attention to threat in healthy adults. Psychopharmacology 2009; 204: 445-455.
39. Southwick SM, Krystal JH, Morgan CA, Johnson D, Nagy LM, Nicolaou A, et al: Abnormal noradrenergic function in posttraumatic stress disorder. Arch Gen Psychiatry 1993; 50: 266-274. (Pubitemid 23115369)
40. Swann AC, Birnbaum D, Jagar AA, Dougherty DM, Moeller FG: Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry 2005; 57: 1209-1211. (Pubitemid 40615785)
41. Hamner MB, Hitri A: Plasma beta-endorphin levels in post-traumatic stress disorder: a preliminary report on response to exerciseinduced stress. J Neuropsychiatry Clin Neurosci 1992; 4: 59-63.
42. Ernst E, Pittler MH: Yohimbine for erectile dysfunction: a systematic review and metaanalysis of randomized clinical trials. J Urol 1998; 159: 433-436. (Pubitemid 28049250)
43. Vogt HJ, Brandl P, Kockott G, Schmitz JR, Wiegand MH, Schadrack J, et al: Doubleblind, placebo-controlled safety and efficacy trial with yohimbine hydrochloride in the treatment of nonorganic erectile dysfunction. Int J Impot Res 1997; 9: 155-161. (Pubitemid 27427272)
44. Van Groenestijn MAC, Akkerhuis GW, Kupka RW, Schneider N, Nolen WA: Structured Clinical Interview for DSM-IV Axis I Disorders, SCID-I (Dutch translation). Lisse, Swets and Zeitlinger, 1996.
45. Van Gerwen LJ, Spinhoven P, Van Dyck R, Diekstra RFW: Construction and psychometric characteristics of two self-report questionnaires for the assessment of fear of flying. Psychol Assess 1999; 11: 146-158. (Pubitemid 29279329)
46. Nousi A, van Gerwen L, Spinhoven P: The Flight Anxiety Situations Questionnaire and the Flight Anxiety Modality Questionnaire: norms for people with fear of flying. Travel Med Infect Dis 2008; 6: 305-310.
47. Granger DA, Kivlighan KT, el-Sheikh M, Gordis EB, Stroud LR: Salivary-amylase in biobehavorial research. Ann NY Acad Sci 2007; 1098: 122-144.
48. Field A: Discovering Statistics Using SPSS, ed 3. London, Sage, 1996.
49. Anker JJ, Carroll ME: Sex differences in the effect of allopregnanolone on yohimbine-induced reinstatement of cocaine seeking in rats. Drug Alcohol Depend 2010; 107: 264-267.
50. Kazdin AE: Research Design in Clinical Psychology, ed 4. Boston, Pearson Education, 2003.